Capital Efficiency 'Under a Microscope'
Tough Economy Means No More Second Chances for Failed Firms
By Jennifer Boggs
Monday, April 20, 2009
"If at first you don't succeed, try, try again," has long been the motto of die-hard biotech investors, who have continued funneling cash into troubled firms - sometimes even in the wake of disastrous clinical results - hoping that the next trial, or the next product will be the success story.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.